Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
48 shown of 2,456 total abstracts
  1. Abstract 11162026-09-01 · 14:00 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    R. Herbst, H. Borghaei, J. Brahmer · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  2. Abstract 15512026-09-05 · 14:00 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    A. Spira, C. Robert · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  3. Abstract 11762026-09-02 · 15:15 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-242
    C. Robert, F. Andre, S. Peters, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  4. Abstract 19372026-09-02 · 16:00 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-415
    L. Paz-Ares, M.C. Garassino, F. Andre · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  5. Abstract 11612026-09-04 · 13:30 CT · E450
    IMpower-189: Tecentriq (atezolizumab) neoadjuvant in TNBC
    C. Robert, E. Winer, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 16942026-09-04 · 14:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-138 study)
    F. Andre, C. Saura · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  7. Abstract 11592026-09-05 · 20:45 CT · Hall B1
    PALOMA-284: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Modi, A. Spira, E. Winer · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  8. Abstract 19132026-09-01 · 18:15 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Robert, S. Tolaney, S. Modi · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  9. Abstract 12292026-09-04 · 15:15 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Antonia, M. Reck, P. Schmid · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  10. Abstract 15602026-09-01 · 21:00 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M. Krop, T. Mok · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  11. Abstract 10212026-09-05 · 18:45 CT · Arie Crown Theater
    DESTINY-Breast-945: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    E. Winer, S. Peters, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  12. Abstract 10192026-09-02 · 20:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    C. Robert, J. Cortes · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  13. Abstract 19582026-09-01 · 14:15 CT · Arie Crown Theater
    MONALEESA-143: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    M.C. Garassino, P. Schmid, F. Andre, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  14. Abstract 10502026-09-04 · 18:30 CT · Hall B1
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-210
    C. Robert, H. Borghaei · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  15. Abstract 11352026-09-04 · 20:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-863
    S. Peters, H. Borghaei, G. Curigliano, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  16. Abstract 10682026-09-03 · 16:15 CT · E450
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    E. Winer, R. Herbst, P. Schmid, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  17. Abstract 10022026-09-04 · 21:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-626
    N. Rizvi, P. Schmid, A. Spira, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  18. Abstract 15932026-09-03 · 14:15 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-117
    J. Cortes, F. Andre, N. Rizvi, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  19. Abstract 18612026-09-01 · 13:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-892 study)
    J. Cortes, H. Rugo, P. Schmid, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  20. Abstract 14292026-09-04 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-416
    S. Tolaney, S. Modi · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  21. Abstract 14532026-09-02 · 16:30 CT · Hall B1
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-914
    F. Andre, S. Tolaney · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  22. Abstract 14932026-09-05 · 20:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-288 study)
    C. Robert, N. Rizvi · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  23. Abstract 14552026-09-02 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    J. Cortes, S. Peters · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 16332026-09-01 · 20:00 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-979 study)
    R. Herbst, C. Saura, S. Peters · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  25. Abstract 17382026-09-03 · 20:00 CT · Hall B1
    PALOMA-607: Ibrance (palbociclib) 1L in HR+ breast cancer
    M.C. Garassino, A. Spira, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  26. Abstract 10622026-09-02 · 18:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-140
    R. Herbst, C. Saura, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  27. Abstract 19712026-09-05 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-707 study)
    E. Winer, H. Borghaei, S. Antonia, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  28. Abstract 14712026-09-01 · 15:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with TNBC
    L. Paz-Ares, M. Reck · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 18732026-09-04 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-322 study)
    L. Paz-Ares, M.C. Garassino, F. Andre, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  30. Abstract 13262026-09-01 · 21:45 CT · Hall B1
    DESTINY-Breast-368: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    S. Modi, L. Paz-Ares, G. Curigliano · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  31. Abstract 17102026-09-03 · 20:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M. Krop, G. Curigliano, F. Andre, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  32. Abstract 12922026-09-04 · 20:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-304
    S. Tolaney, G. Curigliano · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  33. Abstract 17022026-09-02 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    F. Andre, C. Robert, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  34. Abstract 16502026-09-05 · 14:30 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-635
    S. Modi, C. Saura, C. Robert · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  35. Abstract 10422026-09-02 · 20:00 CT · E450
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-642
    T. Mok, S. Peters, P. Schmid · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  36. Abstract 10492026-09-02 · 16:45 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-189
    F. Andre, S. Antonia · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  37. Abstract 18172026-09-02 · 20:15 CT · Hall B1
    MONALEESA-614: Kisqali (ribociclib) 2L in HR+ breast cancer
    A. Spira, G. Curigliano, T. Mok, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  38. Abstract 15682026-09-05 · 13:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-371
    S. Tolaney, H. Rugo · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  39. Abstract 10432026-09-05 · 20:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-187
    H. Rugo, M. Krop, S. Tolaney · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  40. Abstract 14872026-09-04 · 19:00 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-95 study)
    J. Cortes, T. Mok, C. Robert, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  41. Abstract 10112026-09-01 · 13:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-73 study)
    C. Robert, P. Schmid, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 18112026-09-03 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-697 study)
    F. Andre, J. Brahmer, M. Reck · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  43. Abstract 10122026-09-05 · 14:00 CT · Hall B1
    MONALEESA-259: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    N. Rizvi, H. Borghaei, F. Andre, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  44. Abstract 15592026-09-03 · 14:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-775 study)
    M. Reck, M. Krop, L. Paz-Ares, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  45. Abstract 13772026-09-05 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-863 study)
    J. Cortes, C. Saura, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  46. Abstract 11432026-09-02 · 19:45 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-253
    E. Winer, L. Paz-Ares, M. Reck, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  47. Abstract 16462026-09-04 · 21:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-682
    H. Rugo, P. Schmid, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 12392026-09-04 · 19:15 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-290
    S. Antonia, C. Robert, G. Curigliano · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.